Skip to main content
. 2021 Dec 21;75(1):e276–e288. doi: 10.1093/cid/ciab1040

Figure 2.

Figure 2.

Protective effects of mask-wearing and vaccination in the context of high-risk exposure. aORs computed using conditional logistic regression models adjusting for vaccination status, community exposures (listed in the main text), characteristics of high-risk contact, level of anxiety about coronavirus disease 2019 prior to testing, and participants’ age, sex, and region of residence. Regression strata were defined for county reopening tiers and week of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test. An individual was considered fully vaccinated if their SARS-CoV-2 test date was >14 days after their second dose of an mRNA vaccine product (Pfizer/BioNTech BNT-162b2 or Moderna mRNA-1273) or >14 days after their first dose of a single-dose product (Jansen Pharmaceutical Companies JNJ-78436735). In sensitivity analyses limiting to those who received an mRNA vaccine product (excluding N = 25 recipients of JNJ-78436735), the aORs (95% CIs) for incompletely vaccinated and fully vaccinated individuals were 0.30 (.14–.63) and 0.26 (.14–.46), respectively. Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.